Celgene   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Summit NJ United States (1986)
Status: Acquired by Bristol-Myers Squibb (2019)

Organization Overview

First Clinical Trial
1998
NCT00083694
First Marketed Drug
1998
thalidomide (Thalomid)
First NDA Approval
1998
thalidomide (Thalomid)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation | Celgene | CELGENE | Celgene Austria | Celgene/BMS | Celgene Cellular Therapeutics, a division of Celgene Corporation | CELGENE CORP | Celgene Corporation | Celgene Inc | Celgene International II SARL | CELGENE INTL | Celgene KK | Celgene K.K | Celgene K.K. | Celgene Korea | Celgene Medical Director | Celgene Pharmaceutical (Shanghai) Co. Ltd. | Celgene s.r.l. | Celgene Therapeutic Area Head | Clinical Research Manager, Celgene Korea | Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation | Medical Affairs Myeloid Diseases Lead for Celgene Europe | Study physician for Celgene